Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France. As of 2013 Sanofi is the world’s fifth-largest by prescription sales pharmaceutical company. Originally, the company was formed in 1973 and the current incarnation was formed as Sanofi-Aventis in 2004. They also have two locations in the United Kingdom, in Early and Haverhill. They have a presence in Ireland too.
Sanofi currently have over 100,000 company employees in 100 different countries. They have invested over 6 million euros in research and development projects since 2019. They are currently running 91 projects in clinical development. Their healthcare products are available in 170 countries all over the world. Sanofi have 3 core global business units. Specialty care, vaccines and general medicines. With consumer healthcare becoming a stand alone business unit.
Sanofi have a large range of products. This is including prescription medicines, vaccines and consumer healthcare brands, across a broad range of therapeutic areas.
The COVID-19 pandemic places unprecedented demand on science to deliver solutions. Sanofi scientists work harder than ever developing medicines to improve the lives of people living with disease. This company combines a long tradition of leadership in vaccines and small molecules with new strengths in cutting-edge biologics, technologies, and collaborations. R&D teams are solving seemingly intractable biological problems and delivering practice-changing medicines.
Their Research & Development pipeline contains 84 projects. Including 34 new molecular entities in clinical development or that have been submitted to the regulatory authorities. 34 of these projects are already in phase 3 or have been submitted to the regulatory authorities for approval.